[go: up one dir, main page]

WO2015009812A3 - Anti-viral compounds, pharmaceutical compositions, and methods of use thereof - Google Patents

Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Download PDF

Info

Publication number
WO2015009812A3
WO2015009812A3 PCT/US2014/046829 US2014046829W WO2015009812A3 WO 2015009812 A3 WO2015009812 A3 WO 2015009812A3 US 2014046829 W US2014046829 W US 2014046829W WO 2015009812 A3 WO2015009812 A3 WO 2015009812A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pharmaceutical compositions
compounds
viral compounds
viral infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/046829
Other languages
French (fr)
Other versions
WO2015009812A2 (en
Inventor
Shawn P. Iadonato
Kristin M. Bedard
Kerry W. Fowler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kineta Inc
Original Assignee
Kineta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2915874A priority Critical patent/CA2915874A1/en
Priority to AU2014290108A priority patent/AU2014290108A1/en
Priority to CN201480040148.6A priority patent/CN105377253A/en
Priority to US14/895,899 priority patent/US20160122312A1/en
Priority to JP2016527067A priority patent/JP2016528213A/en
Priority to EP14827088.7A priority patent/EP3021843A4/en
Application filed by Kineta Inc filed Critical Kineta Inc
Priority to KR1020167000870A priority patent/KR20160030940A/en
Publication of WO2015009812A2 publication Critical patent/WO2015009812A2/en
Publication of WO2015009812A3 publication Critical patent/WO2015009812A3/en
Priority to IL243608A priority patent/IL243608A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of viral infection, including RNA viral infection, as well as compounds, pharmaceutical compositions, and methods for modulating the RIG-I pathway in a subject and/or in cells. These compounds are isoflavone derivatives, typically substituted at the 3-position with an aryl group and at the 7-position with a heterofunctional group.
PCT/US2014/046829 2013-07-16 2014-07-16 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Ceased WO2015009812A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2014290108A AU2014290108A1 (en) 2013-07-16 2014-07-16 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
CN201480040148.6A CN105377253A (en) 2013-07-16 2014-07-16 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
US14/895,899 US20160122312A1 (en) 2013-07-16 2014-07-16 Anti-viral compounds, pharmaceutical compositions and methods of use thereof
JP2016527067A JP2016528213A (en) 2013-07-16 2014-07-16 Antiviral compounds, pharmaceutical compositions and methods of use thereof
EP14827088.7A EP3021843A4 (en) 2013-07-16 2014-07-16 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
CA2915874A CA2915874A1 (en) 2013-07-16 2014-07-16 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
KR1020167000870A KR20160030940A (en) 2013-07-16 2014-07-16 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
IL243608A IL243608A0 (en) 2013-07-16 2016-01-14 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361846997P 2013-07-16 2013-07-16
US61/846,997 2013-07-16
US201461991417P 2014-05-09 2014-05-09
US61/991,417 2014-05-09

Publications (2)

Publication Number Publication Date
WO2015009812A2 WO2015009812A2 (en) 2015-01-22
WO2015009812A3 true WO2015009812A3 (en) 2015-03-19

Family

ID=52346835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/046829 Ceased WO2015009812A2 (en) 2013-07-16 2014-07-16 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Country Status (10)

Country Link
US (1) US20160122312A1 (en)
EP (1) EP3021843A4 (en)
JP (1) JP2016528213A (en)
KR (1) KR20160030940A (en)
CN (1) CN105377253A (en)
AU (1) AU2014290108A1 (en)
CA (1) CA2915874A1 (en)
IL (1) IL243608A0 (en)
TW (1) TW201542538A (en)
WO (1) WO2015009812A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458492B2 (en) 2011-02-25 2016-10-04 Kineta, Inc. Methods and cells for identifying RIG-I pathway regulators
SG11201900865PA (en) * 2016-08-26 2019-03-28 Univ Kaohsiung Medical Pyrazolylquinoline compound and preparation method thereof and pharmaceutical composition
CN107216243B (en) * 2017-06-07 2020-08-28 四川省中医药科学院 A kind of chalcone analog and its preparation method and use
CN108815191A (en) * 2018-06-25 2018-11-16 青岛大学 RIG-I access, which mediates, acts on HCMV cell anti-virus
CN109251201B (en) * 2018-11-03 2020-06-02 深圳市第二人民医院 An anti-HBV nitrogen-containing heterocyclic compound
CN109232555B (en) * 2018-11-03 2020-06-02 深圳市第二人民医院 anti-HBV oxygen-containing heterocyclic compound
CN110950828B (en) * 2019-11-05 2021-08-17 中国人民解放军第二军医大学 A kind of baicalein or its derivative, preparation method and application
TW202140473A (en) 2020-01-15 2021-11-01 美商纜圖藥品公司 Map4k1 inhibitors
US20220296676A1 (en) * 2020-06-04 2022-09-22 Waterstone Pharmaceuticals(Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CN112225716A (en) * 2020-10-30 2021-01-15 陕西嘉禾生物科技股份有限公司 Synthetic method of chickpea element A
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
AR126442A1 (en) 2021-07-14 2023-10-11 Blueprint Medicines Corp MAP4K1 INHIBITORS
CA3237199A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
CN116554137A (en) * 2022-01-28 2023-08-08 中国科学院上海药物研究所 A cycloalkylaminoalkoxy substituted aryl pyrone compound and its use
JP2025509672A (en) 2022-03-17 2025-04-11 インサイト・コーポレイション Tricyclic urea compounds as JAK2 V617F inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256124A1 (en) * 2004-04-15 2005-11-17 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7618998B2 (en) * 2008-02-26 2009-11-17 Kaosiung Medical University Isoflavone derivatives and pharmaceutical compositions comprising the same
US7880059B2 (en) * 2007-04-26 2011-02-01 The Samuel Roberts Noble Foundation Production of proanthocyanidins to improve forage quality
US20110262482A1 (en) * 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
US20130039887A1 (en) * 2010-04-23 2013-02-14 Kineta, Inc. Methods of Identifying and Using Anti-Viral Compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501180A (en) * 2002-06-27 2006-01-12 ジ エンドウメント フォア リサーチ イン ヒューマン バイオロジー インコーポレイテッド Compounds effective in inhibiting ALDH

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256124A1 (en) * 2004-04-15 2005-11-17 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7880059B2 (en) * 2007-04-26 2011-02-01 The Samuel Roberts Noble Foundation Production of proanthocyanidins to improve forage quality
US7618998B2 (en) * 2008-02-26 2009-11-17 Kaosiung Medical University Isoflavone derivatives and pharmaceutical compositions comprising the same
US20110262482A1 (en) * 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
US20130039887A1 (en) * 2010-04-23 2013-02-14 Kineta, Inc. Methods of Identifying and Using Anti-Viral Compounds

Also Published As

Publication number Publication date
JP2016528213A (en) 2016-09-15
CA2915874A1 (en) 2015-01-22
IL243608A0 (en) 2016-02-29
KR20160030940A (en) 2016-03-21
CN105377253A (en) 2016-03-02
EP3021843A2 (en) 2016-05-25
TW201542538A (en) 2015-11-16
EP3021843A4 (en) 2017-01-04
AU2014290108A1 (en) 2016-02-04
WO2015009812A2 (en) 2015-01-22
US20160122312A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
WO2015009812A3 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
LTPA2019519I1 (en) Macrocyclic derivatives for the treatment of proliferative diseases
MX2016002544A (en) Compounds useful as immunomodulators.
CL2016001737A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
WO2013173759A3 (en) Macrocyclic nucleoside phosphoramidate derivatives
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
WO2013049352A3 (en) Anti-viral compounds
NZ703040A (en) Macrocyclic inhibitors of flaviviridae viruses
LT3251678T (en) BENZOXYOROLOL DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS
HK1221256A1 (en) Microrna compounds and methods for modulating mir-122
HK1217294A1 (en) 4'-fluor0-2'-methyl substituted nucleoside derivatives
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EA201790627A1 (en) STEMULATORS RHC
HK1217489A1 (en) Flap modulators
MX2015000362A (en) Antiproliferative benzo [b] azepin- 2 - ones.
PH12015501088A1 (en) Dimeric compounds
HK1231466A1 (en) Isoindoline derivatives for use in the treatment of a viral infection
CL2014003123A1 (en) 5-amino [1,4], thiazines as bace1 inhibitors; use of the compound against Alzheimer's disease.
WO2013049407A3 (en) Anti-viral compounds
EA201591456A1 (en) MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS
PH12015500399A1 (en) Azaindolines
IL238722B (en) New derivatives of indole for the treatment of cancer, viral infections and lung diseases
WO2012154271A3 (en) Method and cells for identifying rig-i pathway regulators
WO2014113492A3 (en) Anti-viral compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14827088

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2915874

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20167000870

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 243608

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2016527067

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/000684

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016000976

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2014827088

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014290108

Country of ref document: AU

Date of ref document: 20140716

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14827088

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112016000976

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160115